{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:35:21Z","timestamp":1769042121658,"version":"3.49.0"},"reference-count":46,"publisher":"BMJ","issue":"e1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2021,1,4]]},"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1136\/ejhpharm-2020-002652","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T19:23:38Z","timestamp":1611170618000},"page":"e2-e7","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacists\u2019 considerations on non-medical switching at the hospital: a systematic review of the economic outcomes of cost-saving therapeutic drug classes"],"prefix":"10.1136","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4887-2452","authenticated-orcid":false,"given":"Marko","family":"Krstic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe Alain","family":"Devaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshid","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"2024102217105016000_28.e1.e2.1","unstructured":"Organisation for Economic Co-operation and Development (OECD) . Health care systems: getting more value for money. OECD economics department policy notes, no 2 web site, 2010. Available: https:\/\/www.oecd.org\/eco\/growth\/46508904.pdf [Accessed 7 Dec 2018]."},{"key":"2024102217105016000_28.e1.e2.2","unstructured":"Office F\u00e9d\u00e9ral de la Statistique (OFS) . D\u00e9penses de sant\u00e9 dans les pays de l\"OCDE, 2018. Available: https:\/\/www.bfs.admin.ch\/bfs\/fr\/home\/statistiques\/catalogues-banques-donnees\/graphiques.assetdetail.6368414.html [Accessed 7 Dec 2018]."},{"key":"2024102217105016000_28.e1.e2.3","unstructured":"Organisation for Economic Co-operation and Development (OECD) . Health statistics, 2018. Available: http:\/\/www.oecd.org\/health\/health-systems\/health-data.htm [Accessed 7 Dec 2018]."},{"key":"2024102217105016000_28.e1.e2.4","unstructured":"Office F\u00e9d\u00e9ral de la Statistique (OFS) . Financement des d\u00e9penses de sant\u00e9 selon la source. Office F\u00e9d\u00e9ral de la Statistique, 2018. Available: https:\/\/www.bfs.admin.ch\/bfs\/fr\/home\/statistiques\/catalogues-banques-donnees\/publications.assetdetail.6368409.html [Accessed 7 Dec 2018]."},{"key":"2024102217105016000_28.e1.e2.5","unstructured":"Office F\u00e9d\u00e9ral de la Sant\u00e9 Publique (OFSP) . Rapport Sant\u00e92020, 2013. Available: https:\/\/www.bag.admin.ch\/bag\/fr\/home\/strategie-und-politik\/gesundheit-2020\/eine-umfassende-strategie-fuer-das-gesundheitswesen.html [Accessed 10 Dec 2018]."},{"key":"2024102217105016000_28.e1.e2.6","unstructured":"Office F\u00e9d\u00e9ral de la Statistique (OFS) . D\u00e9penses de sant\u00e9 2016: 80.7 milliards de francs au total, 2018. Available: https:\/\/www.bfs.admin.ch\/bfs\/fr\/home\/statistiques\/catalogues-banques-donnees\/communiques-presse.assetdetail.5006749.html"},{"key":"2024102217105016000_28.e1.e2.7","unstructured":"Office F\u00e9d\u00e9ral de la Statistique (OFS) . Co\u00fbt et financement du syst\u00e8me de sant\u00e9, 2018. Available: https:\/\/www.bfs.admin.ch\/bfs\/fr\/home\/actualites\/quoi-de-neuf.assetdetail.6307403.html [Accessed 7 Dec 2018]."},{"key":"2024102217105016000_28.e1.e2.8","unstructured":"Office F\u00e9d\u00e9ral de la Statistique (OFS) . Croissance des co\u00fbts frein\u00e9e dans le domaine hospitalier stationnaire, 2017. Available: https:\/\/www.bfs.admin.ch\/bfs\/fr\/home\/statistiques\/catalogues-banques-donnees\/communiques-presse.assetdetail.6406925.html [Accessed 8 Dec 2018]."},{"key":"2024102217105016000_28.e1.e2.9","unstructured":"Observatoire Suisse de la Sant\u00e9 (Obsan) . Co\u00fbts bruts de l\u2019AOS par groupes de prestations, 2019. Available: https:\/\/www.obsan.admin.ch\/fr\/indicateurs\/couts-de-lassurance-obligatoire-des-soins-aos [Accessed 13 Dec 2018]."},{"key":"2024102217105016000_28.e1.e2.10","unstructured":"Office F\u00e9d\u00e9ral de la Statistique (OFS) . Co\u00fbt du syst\u00e8me de sant\u00e9 selon le fournisseur de biens et services 1) et selon les prestations 2), 2018. Available: https:\/\/www.bfs.admin.ch\/bfs\/fr\/home\/statistiques\/sante\/cout-financement\/cout.html [Accessed 15 Feb 2019]."},{"key":"2024102217105016000_28.e1.e2.11","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199201030-00006"},{"key":"2024102217105016000_28.e1.e2.12","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.11.1666"},{"key":"2024102217105016000_28.e1.e2.13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1185\/03007995.2016.1170673","article-title":"Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review","volume":"32","author":"Nguyen","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"2024102217105016000_28.e1.e2.14","doi-asserted-by":"crossref","unstructured":"Duru OK , Ettner SL , Turk N . Potential savings associated with drug substitution in Medicare Part D: the translating research into action for diabetes (TRIAD) study. J Gen Int Med 2013:1\u20137.","DOI":"10.1007\/s11606-013-2546-6"},{"key":"2024102217105016000_28.e1.e2.15","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903578462"},{"key":"2024102217105016000_28.e1.e2.16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ajhp\/59.6.529","article-title":"Prevalence and cost savings of therapeutic interchange among US hospitals","volume":"59","author":"Schachtner","year":"2002","journal-title":"Am J Health-Syst Pharm"},{"key":"2024102217105016000_28.e1.e2.17","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.4338\/ACI-2016-09-RA-0160","article-title":"ePrescribing: reducing costs through in-class therapeutic interchange","volume":"07","author":"Stenner","year":"2016","journal-title":"Appl Clin Inform"},{"key":"2024102217105016000_28.e1.e2.18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/jamainternmed.2016.1704","article-title":"Estimation of potential savings through therapeutic substitution","volume":"176","author":"Johansen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2024102217105016000_28.e1.e2.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.12.304"},{"key":"2024102217105016000_28.e1.e2.20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jhm.228","article-title":"Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists","volume":"2","author":"Kripalani","year":"2007","journal-title":"JHosp Med"},{"key":"2024102217105016000_28.e1.e2.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2024102217105016000_28.e1.e2.22","doi-asserted-by":"crossref","unstructured":"Drummond MF , Sculpher MJ , Torrance GW , et al . Methods for the economic evaluation of health care programmes. Oxford University Press, 2005.","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"2024102217105016000_28.e1.e2.23","unstructured":"World Health Organization (WHO) . Guidelines for ATC classification and DDD assignment, 2018. Available: https:\/\/www.whocc.no\/news\/guidelines_for_atc_classification_and_ddd_assignment [Accessed 27 Mar 2019]."},{"key":"2024102217105016000_28.e1.e2.24","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/ajhp\/58.18.1734","article-title":"Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol","volume":"58","author":"Ito","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"2024102217105016000_28.e1.e2.25","doi-asserted-by":"crossref","unstructured":"Asias BD , Stock EM , Small NL , et al . Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes. J Diabetes Metab Disord 2015;14.doi:10.1186\/s40200-015-0180-z","DOI":"10.1186\/s40200-015-0180-z"},{"key":"2024102217105016000_28.e1.e2.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02907.x"},{"key":"2024102217105016000_28.e1.e2.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00530-7"},{"key":"2024102217105016000_28.e1.e2.28","unstructured":"Group VPBMSH, and the Medical Advisory Panel . Hydroxymethylglutaryl-Coenzyme A reductase inhibitors (statins), 2002. Available: https:\/\/www.pbm.va.gov\/PBM\/clinicalguidance\/drugclassreviews\/HMGCoAReductaseInhibitorsStatinsDrugClassReviewandAppendices.pdf [Accessed 11 Jun 2019]."},{"key":"2024102217105016000_28.e1.e2.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00965-X"},{"key":"2024102217105016000_28.e1.e2.30","unstructured":"Smith MEB , Lee NJ , Haney E . Drug class review: HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin: final report update 5. Portland OR: Oregon Health & Science University, Portland, Oregon, 2009."},{"key":"2024102217105016000_28.e1.e2.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01085.x"},{"key":"2024102217105016000_28.e1.e2.32","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/ajhp\/55.13.1382","article-title":"Therapeutic-interchange program for oral histamine H2-receptor antagonists","volume":"55","author":"Chase","year":"1998","journal-title":"Amer J Health-Syst Pharm"},{"key":"2024102217105016000_28.e1.e2.33","first-page":"1141","article-title":"Therapeutic substitution of cimetidine for nizatidine was not associated with an increase in healthcare utilization","volume":"6","author":"Good","year":"2000","journal-title":"Am J Manag Care"},{"key":"2024102217105016000_28.e1.e2.34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/001857870003500412","article-title":"Therapeutic Interchange of H2 antagonists: cost savings and impact on outcomes","volume":"35","author":"Howard","year":"2000","journal-title":"Hosp Pharm"},{"key":"2024102217105016000_28.e1.e2.35","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.curtheres.2009.07.001","article-title":"Therapeutic management of uncomplicated gastroesophageal reflux disease in France in 2005: potential cost savings of omeprazole substitution","volume":"70","author":"Mouly","year":"2009","journal-title":"Curr Ther Res"},{"key":"2024102217105016000_28.e1.e2.36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00115677-200816030-00004","article-title":"Clinical and economic effects of a therapeutic substitution policy for proton pump inhibitors in Aboriginal patients in northern communities in Canada\"s Northwest Territories","volume":"16","author":"Gaebel","year":"2008","journal-title":"Dis Man Health Out"},{"key":"2024102217105016000_28.e1.e2.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.12.304"},{"key":"2024102217105016000_28.e1.e2.38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0149-2918(03)80101-7","article-title":"A pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in the Netherlands","volume":"25","author":"van Hout","year":"2003","journal-title":"Clin Ther"},{"key":"2024102217105016000_28.e1.e2.39","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1080\/13696998.2017.1367300","article-title":"The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States","volume":"20","author":"Ng","year":"2017","journal-title":"J Med Econ"},{"key":"2024102217105016000_28.e1.e2.40","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1185\/03007991003613910","article-title":"Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension","volume":"26","author":"Signorovitch","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2024102217105016000_28.e1.e2.41","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2010.488985"},{"key":"2024102217105016000_28.e1.e2.42","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1111\/j.1524-4733.2009.00628.x","article-title":"Cost-Effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea","volume":"12","author":"Lee","year":"2009","journal-title":"Val Health"},{"key":"2024102217105016000_28.e1.e2.43","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/13696998.2017.1347792","article-title":"Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer\u2019s perspective","volume":"20","author":"Permsuwan","year":"2017","journal-title":"J Med Econ"},{"key":"2024102217105016000_28.e1.e2.44","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jval.2011.11.018","article-title":"Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study","volume":"15","author":"Yang","year":"2012","journal-title":"Value Health"},{"key":"2024102217105016000_28.e1.e2.45","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","article-title":"The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"2024102217105016000_28.e1.e2.46","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1185\/030079904X2006","article-title":"Validation of the core diabetes model against epidemiological and clinical studies","volume":"20 Suppl 1","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2020-002652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:11:14Z","timestamp":1729642274000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2020-002652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":46,"journal-issue":{"issue":"e1","published-online":{"date-parts":[[2021,11,29]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/ejhpharm-2020-002652"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2020-002652","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]}}}